DIRS.INFO The most relevant business & tech news

☆ A woman lost 190 pounds from exercise, food journaling, and GLP-1 medication. She's now training for a marathon.
▼ + stars: | 2024-09-16 | by ( Julia Pugachevsky | ) www.businessinsider.com time to read: +4 min

After hiking one mile in the park with her son one day, she realized she felt peaceful afterward. AdvertisementBrown has since lost 190 lbs — 100 pounds from walking, running and dietary changes, and the rest with help from GLP-1 medications, which can assist in dealing with "food noise" and cravings. She started by walking and changing her dietBefore she started running, Brown lost around 70 pounds from walking a few miles every day and making some dietary changes. She ran one mile a day for a monthA few years later, Brown got bored with walking and wanted to try running. She challenged herself to run one mile daily for a month, only running on the treadmill in her house.

Persons: —, Jennifer Brown, Brown, I've, Mounjaro Organizations: Service, Business Locations: Iowa, GLP, Des Moines

☆ We ranked the latest earnings reports from 30 portfolio stocks from great to ugly
▼ + stars: | 2024-09-14 | by ( Zev Fima | ) www.cnbc.com time to read: +14 min

The company may have maintained its full-year revenue outlook, but that was taken as good enough after last quarter's debacle. Management also provided a better-than-expected sales, earnings, and recurring revenue outlook. The Good Abbott Laboratories : Sales, earnings and organic growth all exceeded analyst estimates. Broadcom : Sales and earnings outpaced expectations , driven by strong sales of its AI products and VMware software. Alphabet : Delivered largely better-than expected earnings results that showed the search and cloud giant is finally on better footing in the fast-growing AI space.

Persons: we've, Lisa Su, —, Eli Lilly, Zepbound, Stanley Black, Stanley, Morgan Stanley, Procter, Jim Cramer's, Jim Cramer, Jim, Steve Marcus Organizations: Costco, DuPont, Club, Management, Nvidia, Palo Alto Networks, Good Abbott Laboratories, Broadcom, VMware, Wealth Management, Investment Management, Microsoft, Constellation Brands, TJX, Amazon Web Services, Coterra Energy, GE Healthcare, Honeywell, Gamble, Jim Cramer's Charitable, CNBC, AMD Locations: China, Covid, Dover, Eaton, Palo, North America, GEHC, Wells Fargo, Las Vegas , Nevada, U.S

☆ Morgan Stanley analysts give their favorite stocks to own for the next 12 months
▼ + stars: | 2024-09-13 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

From e-commerce firm Amazon to pharmaceutical giant Eli Lilly , Morgan Stanley's top stocks to own for the next 12 months spans a wide array of sectors. The majority of Morgan Stanley's picks are tilted toward growth, with 67% of the picks meeting that classification. Here's a look at some of the stocks that Morgan Stanley says are worth owning over the next year. Amazon stock has added 23% in 2024. LLY YTD mountain Eli Lilly stock.

Persons: Eli Lilly, Morgan, Morgan Stanley's, Morgan Stanley, Brian Nowak's, Nowak, Terence Flynn's, Eli Lilly's, LLY, Flynn Organizations: Nasdaq, Dow Jones, Amazon, Pharma

☆ Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
▼ + stars: | 2024-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer's drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland. Eli Lilly also announced an $800 million facility expansion in Kinsale, Ireland. Eli Lilly has invested more than $20 billion to buy, build and expand manufacturing plants in the U.S. and Europe since 2020. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , has similarly poured in billions to boost production of its own treatments.

Persons: Eli Lilly, Eli, Edgardo Hernandez, Eli Lilly's Organizations: Novo Nordisk Locations: Indianapolis , Indiana, Ireland, Limerick, U.S, Kinsale, Europe, Novo

☆ The next big market for weight-loss drugs: children
▼ + stars: | 2024-09-11 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Novo Nordisk's American rival, Eli Lilly, has also been testing obesity-beating drugs for children as young as six. Wegovy and similar drugs for weight loss have become a huge business. The drugs' success has made Novo Nordisk the most valuable company in Europe. AdvertisementChildhood obesityAn FDA approval on weight loss drugs for children could open up a new market for Novo Nordisk. In June, US Sen. Bernie Sanders announced that Novo Nordisk CEO Lars Jørgensen would testify before the committee on September 24 at a hearing focusing on the prices that Novo Nordisk charges Americans for their drugs, Ozempic and Wegovy.

Persons: —, Saxenda, Novo, Claudia Fox, Eli Lilly, Goldman Sachs, Wegovy, Sen, Bernie Sanders, Lars Jørgensen, Sanders Organizations: Service, BMI, Business, FDA, Financial Times, Novo Nordisk, Centers for Disease Locations: Madrid, Europe

☆ Sit out the September roller coaster with these steady stocks
▼ + stars: | 2024-09-09 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

A handful of stocks could prove to be smooth sailing for investors looking to ride out a historically volatile September. Stocks got off to a shaky start this month, with last week marking the worst performance since March 2023 for the S & P 500. Shares have advanced about 55% in 2024, and analysts polled by LSEG forecast nearly 11% upside ahead for the pharmaceutical stock. TJX YTD mountain TJX Companies stock. Analysts polled by LSEG forecast more than 12% upside ahead for TJX stock.

Persons: Stocks, Eli Lilly, TJX Organizations: CNBC Pro, CNBC, LSEG, Wall, Marshalls, Brands, Companies, Omnicom, Kroger Locations: Maxx

Several analysts raised their ratings and price targets on Starbucks a day after news that Chipotle CEO would take over at the coffee chain. Starbucks shares rallied on the news, while Chipotle shares fell. He also lowered his price target on shares to $685 from $750, which implies just 6% upside from Monday's close. Chipotle shares pulled back of 7% comes as decelerating trends and a sector rotation already impacted Chipotle's multiple. Since Niccol took the position of CEO in 2018, Chipotle shares surged more than 770%.

Persons: Bernstein, Fatima Boolani, Boolani, — Hakyung Kim, Eli Lilly Eli Lilly's, Berenberg, Lilly, Kerry Holford, " Holford, Morgan Stanley, Keith Weiss, Weiss, Hakyung Kim, Brian Niccol's, Danilo Gargiulo, Gargiulo, Niccol, Chipotle, Laxman Narasimhan, Brian Niccol, Baird, David Tarantino, Fred Imbert Organizations: CNBC, Citi, Palo Alto, Palo Alto Networks, pharma, Intuit, Starbucks, Deutsche Bank, SBUX Locations: Tuesday's

While keeping his outperform rating, Vijay Rakesh chopped $10 off his price target to $145. The Oreo maker should see above-average earnings growth, Jordan said, and the stock itself is a high-quality core holding. — Alex Harring 5:50 a.m.: UBS lays out earnings expectations for Nvidia UBS is remaining bullish on Nvidia heading into the artificial intelligence giant's earnings report. Analyst Timothy Arcuri reiterated his buy rating and $150 price target heading into earnings expected later this month. His price target of $23, up from $20, implies a gain of 28.3% over the next 12 months.

Persons: Piper Sandler, Vijay Rakesh, Rakesh, Alex Harring, Shaun Kelley, Kelley, — Alex Harring, Eli Lilly, Eli Lilly's, James Shin, Shin, Jefferies, Samad Samana, Samana, Goldman, Goldman Sachs, Mills, Leah Jordan, Jordan, Kraft Heinz, Timothy Arcuri, Arcuri, Patrick Moley, Morley, HOOD, Fred Imbert Organizations: CNBC, UBS, Mizuho, Micron, Seagate Technology, Western, Bank of America, Gaming, Consumer, Terre Haute, Kentucky Derby, Deutsche Bank, Par Technology, Jefferies, Conagra Brands, Hershey, Nvidia UBS, Nvidia Locations: Churchill, Northern, Northern Virginia, Kentucky, Robinhood

☆ Wells Fargo says buy stocks, not the stock market now. Here's its bargain list
▼ + stars: | 2024-08-09 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Recent market turbulence has unearthed some bargain prices for momentum stocks, according to Wells Fargo. He suggests that investors "buy stocks, not the stock market." Here's a closer look at stocks Wells Fargo is eyeing in light of the recent market volatility. Shares of the Facebook parent have gained roughly 45% in 2024, but have slumped 3% over the past month. Eli Lilly has climbed 53% in 2024, but is down roughly 8% over the past month.

Persons: Wells, Christopher Harvey, Harvey, Harvey isn't, Blayne Curtis, Eli Lilly, Lilly, Zepbound Organizations: Services, Nvidia, Jefferies, Facebook, Meta, LSEG, Netflix Locations: Wells Fargo, U.S, Wells

☆ If you invested $1,000 in drugmaker Eli Lilly 10 years ago, here's how much money you'd have now
▼ + stars: | 2024-08-08 | by ( Cheyenne Devon | ) www.cnbc.com time to read: +2 min

One of the world's most valuable drug manufacturers by market capitalization reported its second-quarter earnings results Thursday, and they were impressive. Zepbound was approved Nov. 8 by the U.S. Food and Drug Administration as a treatment for weight management and obesity, according to Eli Lilly. In its first full quarter in the U.S. market, Zepbound brought in $517.4 million in revenue, Eli Lilly reported in April. "We just see unbelievable demand, and we're not even trying that hard to promote this drug," Eli Lilly CEO David Ricks told CNBC during a "Squawk Box" interview Thursday. And drug manufacturers such as Eli Lilly and Novo Nordisk, the pharmaceutical company that makes Ozempic and Wegovy, are racing to meet that demand.

Persons: you've, Eli Lilly, it's, Zepbound, we're, David Ricks, Morgan Stanley's Organizations: U.S . Food, Drug Administration, CNBC, Centers for Disease Control, Pew Research Center, Novo Nordisk Locations: U.S, United States

☆ Eli Lilly's second quarter eases Zepbound pricing fears and suggests it's making headway in weight loss race
▼ + stars: | 2024-08-08 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Lilly's shares are up more than 7% on the news. LLY YTD mountain Eli Lilly shares year to date. The first followed positive reports from rivals that showed they were making progress in developing their own weight loss drugs . However, sales rose 59% for Mounjaro quarter over quarter and were up 140% for Zepbound as Lilly saw better pricing. Meanwhile, analysts see several events on the horizon that could further boost Lilly's shares in coming months.

Persons: Eli Lilly, Bansal, Lilly, Carter Gould, Lilly's headwinds, Novo's, Wells Fargo's Bansal, Evan David Seigerman, Chris Schott, Schott, Lilly's Organizations: Novo Nordisk, Wells, Barclays, Nordisk, BMO Capital Markets, Food and Drug Administration Locations: Wells Fargo, Lilly's, Wednesday's

☆ A man lost 100 pounds and kept them off by making two simple lifestyle changes
▼ + stars: | 2024-08-08 | by ( Kim Schewitz | ) www.businessinsider.com time to read: +7 min

"I lost weight, but it wasn't in the healthiest way. AdvertisementXavier lost 100 pounds in high school on a restrictive diet, but it was "unsustainable," he said. Benji Xavier lost 100 pounds by making healthier versions of his favorite foods at home. AdvertisementXavier has maintained his weight loss by making healthy lifestyle changes. He has "cheat days," and eats whatever he wants on holiday without feeling guilty because he knows he'll return home to a healthy lifestyle.

Persons: —, Benji Xavier, Xavier, He's, unconfident, It's, he'll, it's, I'm Organizations: Service, Business, Centers for Disease Control, CDC Locations: New Jersey

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
▼ + stars: | 2024-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

Shares of Eli Lilly closed more than 9% higher on Thursday. That has forced Eli Lilly and its rival Novo Nordisk to invest heavily to boost manufacturing. "We just see unbelievable demand, and we're not even trying that hard to promote this drug," Eli Lilly CEO David Ricks told CNBC in an interview. Eli Lilly said sales were largely driven by higher demand for Mounjaro and Zepbound as production increases improved supply in the U.S. With a market cap of more than $730 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Eli Lilly's, we're, David Ricks, Ricks, Zepbound, Mounjaro, Wegovy Organizations: U.S, Novo Nordisk, Food, CNBC, LSEG Locations: U.S, United States, Novo

☆ A man rapidly lost weight on a popular weight-loss drug. After 6 months, he was hospitalized with heart problems and confusion.
▼ + stars: | 2024-08-07 | by ( ) www.businessinsider.com time to read: +4 min

Read previewSix months after he started taking a weight-loss drug, a 62-year-old man was hospitalized with heart palpitations, tremors, confusion, fever, and sweating. The man, from Colorado, had been prescribed the drug tirzepatide (the active ingredient in Mounjaro and Zepbound) to lose weight. Over time, the patient decreased his insulin dose as he lost weight, but didn't change his thyroid medication. This highlights the potential risks of losing weight too quickly, and the need for medical supervision while using the drugs, they said. AdvertisementOzempic and Wegovy, brand names for semaglutide showed weight loss of about 15% over a similar time period.

Persons: —, Barbara Davis, they've Organizations: Service, Business, Barbara, Barbara Davis Center, Diabetes, University of Colorado, FDA Locations: Colorado

☆ Here's why Eli Lilly is down heading into earnings — and how we plan to play it
▼ + stars: | 2024-08-07 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Eli Lilly shares declined 1.7% Wednesday after peer Novo Nordisk posted disappointing earnings results before the bell. Investors are weighing if the same fate is in store for Club holding Eli Lilly and its GLP-1 drugs Zepbound and Mounjaro. Still, Jim said Eli Lilly shares could fall further after the drugmaker releases its own quarterly results on Thursday. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Dow, Eli Lilly, —, Jim, That's, Jim Cramer's Organizations: CNBC, Dow Jones Industrial, Nasdaq, Novo Nordisk, Club, Novo Nordisk's, CVS, Management

☆ Eli Lilly reports earnings Thursday. Here's what Wall Street is watching
▼ + stars: | 2024-08-07 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.

Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema

☆ Here are 4 things we're watching closely in the stock market this week
▼ + stars: | 2024-08-04 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Stocks had a rough week, topped off with a pummeling Friday after the July jobs data came in weaker than expected. Until then, bad economic news was good news for the stock market, because it meant the Federal Reserve would start cutting interest rates sooner. On Thursday, a drop in U.S. manufacturing activity for July and a jump in initial jobless claims dragged down the market. Next week is light on economic data, so expect earnings reports and CEO commentaries to drive the market action. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Stocks, Dow Jones, Jim Cramer, would've, Eli Lilly, Mounjaro, Berkshire Hathaway, Krystal, Tyson, BAX, Owens, Walt, Oscar Health, CRON, Krispy, Papa, Jim Cramer's, Jim Organizations: Nasdaq, Dow, Reserve, Broadcom, Devices, Palo Alto, PMI, Wynn Resorts, Investors, Wynn, Wynn Palace, U.S . Disney, Management, and Drug Administration, Carlyle Group, Krystal Biotech, Tyson Foods, TSN, Alpha Metallurgical Resources, BioCryst Pharmaceuticals, Axsome Therapeutics, Technologies, Clover Health, Realty Income Corp, Avis Budget Group, CSX Corp, CSX, Simon Property Group, Sterling Construction Company, Teradata Corp, Yum China Holdings, ZoomInfo Technologies, Holdings, Caterpillar, Baxter International, Vulcan Materials Company, Allegheny Technologies Incorporated, Constellation Energy Group, Marathon Petroleum Corp, Owens Corning Inc, Duke Energy Corp, GXO Logistics, Brands, Builders, Wynn Resorts Ltd, WYNN, Rivian Automotive, Devon Energy Corp, GigaCloud Technology Inc, Lumen Technologies, VF Corp, Walt Disney Co, Novo Nordisk, CVS Health, Aurora Cannabis Inc, Emerson Electric Co, Sony Group Corporation, SONY, Inc, ODP Corporation, Icahn Enterprises, MannKind Corp, ACM Research, Brink's Company, AppLovin Corporation, Digital Turbine, Sarepta Therapeutics, Occidental Petroleum Corp, Bros, SolarEdge Technologies, Aspen, Coeur D'Alene Mines Corp, Co, Vistra Energy, Cheniere Energy, Cronos, Himax Technologies, Properties Trust, Papa John's, Paramount Global, Trade, Lab, B2Gold Corp, Honest Company, Gilead Sciences, Growth, Nikola Corporation, Embraer, New Fortress Energy, Construction, Jim Cramer's Charitable, CNBC, Disney, Pixar Locations: Palo, Macau, Las Vegas, Boston, Vegas, Wynn Macau, China, Novo, Coeur, Gilead

☆ Earnings playbook: Disney and this industrial giant are among companies slated to report this week
▼ + stars: | 2024-08-04 | by ( Fred Imbert | ) www.cnbc.com time to read: +4 min

More than 70 S & P 500 names are slated to report this week, including Disney and Caterpillar . Tuesday Uber Technologies is set to report earnings before the bell. This quarter: The ride-hailing giant is expected to report a 70% year-over-year increase in earnings, LSEG data shows. What history shows: Uber has beaten earnings expectations in six of the last seven quarters, according to data from Bespoke Investment Group. Wednesday Walt Disney is set to report earnings before the open.

Persons: Eli Lilly, Benjamin Black, Uber, Walt Disney, Wells, Steven Cahall, LLY, Eli Lilly's Organizations: Disney, Caterpillar . Pharmaceutical, behemoth, CNBC, Technologies, Investors, Autonomous Vehicle, Deutsche Bank, Investment, Caterpillar, JPMorgan Locations: California

Jim Cramer said Friday the Fed should have cut at this week's meeting. Those were in place with AMD because Jim Cramer mentioned the stock on CNBC TV over the past 72 hours. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Dow Jones, here's, Eli Lilly, Jim Cramer's, Jim Organizations: CNBC, Dow Jones, Nasdaq, Federal Reserve, Fed, Bond, chipmaker Broadcom, AMD, Palo Alto, Nvidia, Wynn Resorts, Disney, Jim Cramer's Charitable Locations: U.S, DuPont, Dover, Wells

☆ Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says
▼ + stars: | 2024-08-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug Administration's drug shortage database on Friday. The FDA's update comes one day after Eli Lilly CEO David Ricks told Bloomberg that the shortages of Mounjaro and Zepbound would end "very soon." A spokesperson for Eli Lilly did not immediately respond to CNBC's request for comment on the FDA's update on Friday. Meanwhile, the FDA said some doses of Novo Nordisk's weight loss drug Wegovy have limited supply.

Persons: Eli Lilly’s, Eli Lilly's, Zepbound, Eli Lilly, David Ricks Organizations: U.S . Food, Novo Nordisk, Bloomberg, FDA Locations: New York City, U.S

☆ Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer’s in early trial
▼ + stars: | 2024-07-30 | by ( Meg Tirrell | ) edition.cnn.com time to read: +7 min

“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said. The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30. The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP. But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s. GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.

Persons: liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide Organizations: CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s Locations: United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish

☆ Weight-loss drugs could stave off dementia, small study finds
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.

Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo

☆ Scientists say weight-loss drugs could protect our brains from dementia. Early results suggest they're onto something.
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

Search resuls for: "Mounjaro"

25 mentions found